Indeed, FACS analysis demonstrated decreased naïve T cell (CD62L+CD44-) and increased effector-memory T cell (CD62L-CD44+) within tumor-associated CD8+ T cells in BAY-I treated withdrawal cohort as compared to vehicle cohort (Fig. 7E). Here, CD8A is linked to neoplasm.